menu
    • menu

    Company profile for Neurophth Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Wuhan Newforth Biotechnology Co., Ltd. is China's first ophthalmology gene drug research and development company, located in Wuhan Optics Valley Biological City, a state-level biological industrial park. Committed to the research and drug development of gene therapy for eye genetic diseases. Newforth first chose Leber hereditary optic neuropathy (LHON) as a breakthrough. Since 2008, a lot of basic research has been carried out...
    Wuhan Newforth Biotechnology Co., Ltd. is China's first ophthalmology gene drug research and development company, located in Wuhan Optics Valley Biological City, a state-level biological industrial park. Committed to the research and drug development of gene therapy for eye genetic diseases. Newforth first chose Leber hereditary optic neuropathy (LHON) as a breakthrough. Since 2008, a lot of basic research has been carried out. In 2011, the world ’s first clinical study of gene therapy for Leber hereditary optic neuropathy was completed, and 9 patients participated in clinical research.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Neurophth TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    Wuhan National Bio-Industry Base Project B, C, D R & D Building B1, No. 666 Ga...
    Telephone
    Telephone
    027-65524119
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neurophth.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/neurophthtx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neurophth Announces Completion of Patient Enrollment for Opvika Phase I/II Trial
    Neurophth Announces Completion of Patient Enrollment for Opvika Phase I/II Trial

    19 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurophth-announces-completion-of-patient-enrollment-for-opvika-phase-iii-clinical-trial-in-the-us-302064859.html

    PR NEWSWIRE
    19 Feb 2024
    Share Share
    Neurophth Announces First Patient Dosed in Ph I/II Trial of Second Gene Therapy
    Neurophth Announces First Patient Dosed in Ph I/II Trial of Second Gene Therapy

    17 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurophth-announces-first-patient-dosed-in-phase-iii-clinical-trial-of-second-gene-therapy-301903288.html

    PR NEWSWIRE
    17 Aug 2023
    Share Share
    Neurophth Secures $95M in Series C+ Financing for Clinical Trials
    Neurophth Secures $95M in Series C+ Financing for Clinical Trials

    14 Aug 2023

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2023-08-14/neurophth-secures-95m-in-series-c-financing-for-gene-therapy-clinical-trials/?widget=listSection

    CONTRACT PHARMA
    14 Aug 2023
    Share Share
    Neurophth Completes Enrollment for PIII trial for gene therapy treatment of LHON
    Neurophth Completes Enrollment for PIII trial for gene therapy treatment of LHON

    21 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/commercialization-of-gene-therapy-is-coming-soon-neurophth-completes-patient-enrollment-for-phase-iii-clinical-trial-for-the-gene-therapy-treatment-of-lhon-301751494.html

    PR NEWSWIRE
    21 Feb 2023
    Share Share
    Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON
    Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON

    19 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neurophth-receives-ind-clearance-from-fda-for-aav-nd1-gene-therapy-of-lhon-301705927.html

    PRNEWSWIRE
    19 Dec 2022
    Share Share
    Cyagen and Neurophth partner to develop gene therapy vectors
    Cyagen and Neurophth partner to develop gene therapy vectors

    08 Nov 2022

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/cyagen-neurophth-gene-therapy/

    PHARMACEUTICAL-TECHNOLOGY
    08 Nov 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search